GW Pharmaceuticals PLC (NASDAQ:GWPH)

Monday’s Trading Day
88.40 +1.94 / +2.24%
As of Mar 30
Day’s Change
Tuesday’s Pre-Market   Switch to standard view »
90.60 +2.20 / +2.49%
Volume: 200.00
Health Technology
Pharmaceuticals: Other

Company Description

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Sativex Commercial, Sativex Research & Development and Pipeline Research & Development. The Sativex Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.

Contact Information

GW Pharmaceuticals Plc
Porton Down Science Park
Salisbury Wiltshire SP4 0JQ
Investor Relations:
(917) 280-2424



Other institutional38.92%
Mutual fund holders32.08%
Individual stakeholders--

Top Executives

Justin D. GoverChief Executive Officer & Executive Director
Christopher John ToveyChief Operating Officer & Executive Director
Adam David GeorgeCFO, Secretary & Executive Director
Richard PottsDirector-Clinical Operations
Colin StottDirector-Research & Development Operations

To view my watchlist

Not a member yet?

Sign up now for a free account